Skip to main content

Table 1 Clinico-radiological and pathological features of the patients with BCBM

From: Analysis of stromal PDGFR-β and α-SMA expression and their clinical relevance in brain metastases of breast cancer patients

Variable

No.

Percent

Age (year)

< 60

35

70%

≥ 60

15

30%

Sex

Female

49

98%

Male

1

2%

Molecular type

Luminal A

10

20%

Luminal B

6

12%

HER2

19

38%

TN

15

30%

CAF pattern

Type A

24

48%

Type B

20

40%

Type C

6

12%

PDGFR-β

Low

27

54%

High

23

46%

α-SMA

Low

27

54%

High

23

46%

Tumor location

Supratentorial

37

74%

Infratentorial

13

26%

Extracranial Mets

Absent

12

24%

Present

38

76%

BM symptom

Mild to moderate

31

62%

Severe

19

38%

KPS

≥ 80

32

64%

< 80

18

36%

BM multiplicity

Single

24

48%

Multiple

26

52%

BM development

Metachronous

49

98%

Synchronous

1

2%

BM size

< 4 cm

22

44%

≥ 4 cm

28

56%

Peritumoral edema

Mild to moderate

27

54%

Severe

23

46%

Tumor nature

Solid

27

54%

Cystic or mixed

23

46%

Resection degree

Gross total

38

76%

Partial to subtotal

12

24%

Postoperative RT/GKS

Absent

16

32%

Present

34

68%

  1. BC, breast cancer; BM, brain metastasis; α-SMA, alpha-smooth muscle actin; CAF, cancer-associated fibroblast; GKS, gamma knife radiosurgery; KPS, Karnofsky performance score; Mets, metastasis; PDGFR-β, platelet-derived growth factor receptor-beta; RT, radiation treatment; TN, triple negative